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Introduction: Esophageal squamous cell carcinoma (ESCC) is a 
cancer of variable outcomes with limited effective treatments result-
ing in poor overall survival (OS). Epigenetic alterations contributing 
to this deadly cancer type that can be used as novel therapeutic or 
diagnostic targets are still poorly understood.
Methods: We explored genome-wide DNA methylation data 
from The Cancer Genome Atlas project and identified a panel of 
tumor-related genes hypermethylated in ESCC. The methylation 
statuses of RASSF1, RARB, CDKN2A (p16INK4a, p14ARF), APC, 
and RUNX3 genes and long interspersed nucleotide element-1 
(LINE-1) were validated in a large cohort (n = 140) of clinically 
well-annotated ESCC specimens and esophageal normal mucosa 
(n = 28) using a quantitative methylation-specific polymerase 
chain reaction.
Results: Hypermethylation of RARB, p16INK4a, RASSF1, APC, 
RUNX3, and p14ARF were observed in 55%, 24%, 20%, 19%, 14%, 
and 8% of specimens, respectively. Hypermethylation of APC was 
significantly associated with tumor depth (p = 0.02) and American 
Joint Committee on Cancer stage (p = 0.03). Global DNA methyl-
ation level, assessed by LINE-1, was significantly lower in ESCC 
than in normal mucosa (p < 0.0001), and lower in greater than or 
equal to T2 (n = 69) than T1 tumors (n = 45; p = 0.03). There was 
a significant inverse correlation between LINE-1 and RARB meth-
ylation (p = 0.008). Importantly, hypermethylation of RASSF1 and 
APC genes was significantly associated with overall survival (OS; 
p = 0.006 and p = 0.007, respectively). In addition, patients with 
tumors containing a higher number of methylated genes (greater than 
two genes) presented worse OS (p = 0.003).
Conclusions: This study demonstrates that epigenetic alterations of 
a panel of tumor-related genes and the noncoding region LINE-1 can 
be used as prognostic indicators and help in clinical management of 
ESCC patients.
Key Words: Esophageal squamous cell carcinoma, LINE-1, DNA 
methylation, Prognosis, Tumor-related genes.
(J Thorac Oncol. 2015;10: 509–517)
Esophageal cancer can be differentiated into two histological subtypes: squamous cell carcinoma and adenocarcinoma. 
Esophageal squamous cell carcinoma (ESCC) is a common 
malignancy worldwide, and its incidence is known to be high 
in African and Asian countries, particular in China, India, 
Japan, and other Southeast Asian countries.1 In general, over-
all 3- and 5-year survival rates for ESCC patients who under-
went esophagestomy have been reported to be 31.1–52.5% 
and 20.8–40.0%, respectively.2,3 Although recent advances 
in surgical techniques and the introduction of preoperative 
chemoradiotherapy have been shown to significantly improve 
ESCC patients’ survival, ~30% of patients still develop tumor 
recurrence by the time of 5-year follow-up.4 Therefore, it is 
critical to improve risk assessment that can identify patients 
at high risk for recurrence. ESCC has defined clinicopatho-
logical prognostic factors such as lymph node metastasis, 
depth of tumor invasion, grade of differentiation, and family 
history; however, new prognostic factors are still needed to 
assess tumor progression and disease outcome.2,5 Although 
some genomic aberrations have been recently identified as 
potential biomarkers for ESCC,6,7 the clinical or pathological 
significance of these biomarkers is still not clear. Further stud-
ies to identify novel molecular alteration of ESCC are urgently 
needed.
ESCC etiology is often correlated with excessive con-
sumption of carcinogenic substances such as alcohol and 
tobacco.8,9 Tobacco exposure has been correlated with aber-
rant promoter hypermethylation of selected genes in esopha-
geal noncancerous mucosae.10 Although the mechanism of 
ESCC progression is poorly understood, it is suggested that 
epigenetic events may be involved.11 Therefore, identifying 
aberrant epigenetic events is important to understand the 
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ESCC progression and also to develop new potential bio-
markers for ESCC. Genome-wide DNA hypomethylation and 
gene-specific hypermethylation are common epigenetic events 
in tumorigenesis for many types of carcinomas. Tumor-related 
gene (TRG) promoter CpG island hypermethylation is a well-
recognized mechanism of transcriptional silencing.12 Aberrant 
DNA methylation of TRG promoter regions has been recog-
nized in different tumor cells.13,14 Approximately 45% of the 
human genome is composed of transposable elements with 
interspersed repeats. Long interspersed nucleotide element-1 
(LINE-1)15 is the most abundant human non-long terminal 
repeat retrotransposable element, accounting for about 20% 
of the genome. Transcriptionally activated LINE-1 is related 
to hypomethylation of its promoter region. LINE-1 can be 
transposed, via reverse transcription, to different genomic 
regions causing disruption of genes and leading to genomic 
instability.16 LINE-1 is hypermethylated in normal cells and 
has been shown to be hypomethylated in several types of car-
cinomas.17–20 Our hypothesis is that epigenetic aberrations of 
key TRGs and LINE-1 are related to ESCC progression and 
disease outcome.
Using highly sensitive assays, absolute quantitative 
assessment of methylated alleles,14 and methylation-specific 
PCR (MSP), we examined whether genome-wide hypomethyl-
ation and TRG-specific hypermethlyation contribute to ESCC 
progression and disease outcome. Initially, we explored TRGs 
in ESCC using genome-wide DNA methylation data from 
The Cancer Genome Atlas (TCGA) project. A panel of six 
CpG islands located in RASSF1, RARB, p16INK4a, RUNX3, 
APC, and p14ARF genes were significantly hypermethylated 
in ESCC. Several of these regions have been described to be 
hypermethylated21–24 and correlated with disease outcome to 
some extent in ESCC.25,26 RASSF1, RARB, and RUNX3 gene 
hypermethylations have been shown to positively correlate 
with ESCC progression.22–24,27 However, they have not been 
assessed in combination for ESCC primary tumor progression 
and overall disease outcome.
In this study, we identified a panel of epigenetic bio-
markers for ESCC, including hypomethylation assessed by 
quantitative LINE-1 methylation and hypermethylation of six 
TRGs. This novel panel was shown to have significant prog-
nostic utility in disease outcome in a multivariate analysis.
METHODS
Patients and Specimens
Representative blocks of paraffin-embedded archi-
val tissue specimens were collected from 114 patients with 
ESCC that underwent surgery at Keio University Hospital 
in Tokyo, Japan from 1997 until 2002. The study design was 
approved by the institutional review board of Keio University. 
Since 1994, patients with suspected T4 tumors underwent 
chemoradiotherapy with 5-fluorouracil and cisplatin with a 
final objective of tumor irradiation. If downstaging was suc-
cessful, patients underwent elective resection. In this cohort, 
none of the patients had prior chemoradiotherapy. Of the 114 
ESCC patients, corresponding paired 26 available lymph node 
metastases were studied. In addition, from the primary tumor 
sections, adjacent normal esophageal epithelia (greater than 
1 mm separated from cancer cells) were microdissected as 
normal control (n = 28, American Joint Committee on Cancer 
[AJCC] stage: I [n = 12], IIA [n = 2], IIB [n = 10], or III 
[n = 4], gender: male [n = 25], and female [n = 3], age: 44–75 
[Mean = 60]). Patients were classified according to AJCC 
criteria.
DNA Isolation and Sodium 
Bisulfite Modification
Genomic DNA was extracted from paraffin-embedded 
archival tissue and the concentration was determined as we 
previously described.28 An aliquot of 300 ng was subject to 
a sodium bisulfite modification reaction, as we previously 
described.28
Quantitative Analysis of 
Hypomethylated LINE-1
In a previous study, we introduced the absolute quanti-
tative assessment of methylated alleles assay based on bisul-
fate-modified DNA and real-time polymerase chain reaction 
(PCR) using two TaqMan minor groove binder (MGB) probes 
labeled with different fluorophores.14,29,30 In brief, a universal 
set of primers is utilized to amplify sodium bisulfite-modi-
fied LINE-1, despite its methylation status. These primers 
were designed as we previously described.20 Then, a pair of 
MGB probes are utilized to specifically amplify methylated 
and unmethylated sequences for quantitative analysis. PCR 
amplification was performed with PCR buffers and forward/
reverse primers, methylated- and unmethylated-specific MGB 
probes, dNTPs, 0.7 U of AccuStart Taq DNA polymerase 
(Quanta BioSciences, Gaithersburg, MD), and 1 μl bisulfite-
treated DNA. Samples were amplified with a precycle hold at 
95°C (10 min), followed by 45 cycles of denaturation at 95°C 
(15 sec), and annealing and extension at 60°C (1 min). The 
standard curve for quantifying methylated and unmethylated 
copy numbers was generated by a threshold cycle of serial 
dilutions of plasmid templates (106 to 101 copies). The mean 
of triplicate experiment was used as the copy number. LINE-1 
hypomethylated controls (melanoma lines) and LINE-1 meth-
ylated controls (normal peripheral blood leukocytes) were 
included as assay controls in each 384-well-PCR microplates. 
The hypomethylated LINE-1 level was defined as the copy 
number of unmethylated LINE-1 relative to the sum of the 
copy number of methylated and unmethylated LINE-1 (U/U 
+ M), referred as the LINE-1 U Index. The LINE-1 U index 
levels of each sample were compared as a representation of 
hypomethylated LINE-1 status.
Genome-Wide DNA Methylation Analysis 
of ESCC and Normal Esophagus
Genome-wide DNA methylation data for 38 ESCCs and 
12 normal esophagus tissues (Supplementary Table 2, SDC 
1, http://links.lww.com/JTO/A757) generated using Illumina 
Human Methylation 450K (HM450K) was obtained from 
TCGA.31 First, DNA methylation level of 4415 CpG sites 
located in 182 previously reported TRGs (Supplementary 
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Table 3, SDC 1, http://links.lww.com/JTO/A757) was com-
pared between ESCC and normal esophagus tissues. DNA 
methylation differences for each CpG site in regards to sig-
nificance were visualized in a Volcano Plot. Terrain maps were 
utilized to visualize the distance generated by CpG methyla-
tion profiles for each sample. Finally, hierarchical clustering 
with bootstrapping analyses was employed to identify clusters 
of hypermethylated CpG sites on ESCCs specimens.
Detection of Gene-Specific 
Promoter Hypermethylation
Bisulfite-modified DNA was used as a template for 
separate PCRs with fluorescently labeled primer sets spe-
cific for methylated or unmethylated versions of six TRGs 
(Supplementary Table 1, SDC 1, http://links.lww.com/JTO/
A757). PCRs were performed as previously described.20 
Amplifications were carried out as follows: 95°C for 3 min 
followed by 36–40 cycles of denaturation at 95°C (30 sec), 
annealing (30 sec), extension at 72°C (30 sec), and a final 
72°C cycle (7 min extension).
PCR products were analyzed by capillary array elec-
trophoresis (CEQ 8000XL; Beckman Coulter, Brea, CA) 
using Beckman Coulter WellRED dye-labeled phosphorami-
dites (Genset Oligos, La Jolla, CA) as previously described.32 
Leukocyte DNA from healthy donors were methylated in vitro 
with excess SssI methyltransferase (New England BioLabs, 
Ipswich, MA) to generate methylated DNA as a universal 
methylated control.33 Peripheral blood leukocytes DNA from 
healthy donors were amplified by phi-29 DNA polymerase 
and served as a universal unmethylated control. Each assay 
included ESCC specimens, two positive (DNA from a known 
methylated cell line and universal methylated control) and two 
negative (DNA from a known unmethylated cell line and uni-
versal unmethylated control) controls. Representative figures 
of TRG MSP are presented in Supplementary Figure 1 (SDC 
2, http://links.lww.com/JTO/A758).
Biostatistical Analysis
The study was performed in concordance with the 
Reporting Recommendations for Tumor Marker Prognostic 
Studies of the National Cancer Institute.34 To compare para-
metric variables, Student’s t and ANOVA tests were used, 
while to compare nonparametric variables, Wilcoxon rank 
sum and Kruskal–Wallis tests were employed. Associations 
between categorical variables were assessed using the χ2 or 
Fisher’s exact tests. Trend analysis of LINE-1 unmethylated 
(or nonmethylated) status across AJCC stages was performed 
using the Cochran Armitage trend test. The Newman–Keuls 
multiple comparison test was used to determine whether each 
AJCC stage differed significantly in regards to methylation 
level. For the LINE-1 hypomethylation level-based discrimi-
nation between primary ESCC and adjacent normal mucosa, 
the receiver operating characteristics curve was generated and 
the area under the curve was calculated. Overall survival (OS) 
curves were generated using the Kaplan–Meier method and 
survival estimates were compared using the log-rank test for 
univariate survival analysis. In the univariate survival analysis, 
the LINE-1 U index, individual TRGs, and known prognostic 
factors such as depth of tumor invasion, pathological differ-
entiation, AJCC stage, status of lymph node metastasis, or the 
number of metastatic nodes were examined. The variables that 
showed a trend of association to survival (p < 0.1) in the univari-
ate analysis were entered into the multivariate Cox proportional 
hazard regression model. A stepwise selection method was used 
to obtain the final survival model. Proportional hazard assump-
tion for the final model was tested using the Cox Snell residual 
plot. Biostatistical analyses were performed using SAS (version 
9.2), and p ≤ 0.05 was considered significant.
Genome-wide DNA methylation data was compared 
between groups using the Wilcoxon rank-sum test, and mul-
tiple comparisons were corrected using the Benjamini and 
Hochberg false discovery rate method. Unsupervised hierar-
chical cluster and terrain map analyses were performed using 
the Euclidean metric distance and the topology of the phenetic 
tree was evaluated by Bootstrap analysis with 100 iterations in 
MultiExperiment Viewer v4.9 (Dana-Farber Cancer Institute, 
Boston, MA).35
RESULTS
Patient Characteristics
The study included 114 ESCC eligible consecutive 
patients who underwent surgery with follow-up at Keio 
University Hospital from 1997 until 2002, and excluded ESCC 
patients with prior chemoradiotherapy. Table 1 summarizes 
TABLE 1.  Patients Demographics and Pathology 
Characteristics
Gender
  Male 106 (93%)
  Female 8 (7%)
Age
  Mean ± SD 60.9 ± 7.46 (range, 39–81)
Primary tumor (T)
  T1 45 (39%)
  T2 11 (10%)
  T3 54 (47%)
  T4 4 (4%)
Regional lymph nodes (N)
  N0 42 (37%)
  N1 71 (62%)
  Unknown 1 (1%)
AJCC stage
  Stage I 28 (25%)
  Stage IIA 14 (12%)
  Stage IIB 26 (23%)
  Stage III 46 (40%)
Histological differentiation
  Well 27 (24%)
  Moderate 72 (63%)
  Poor 11 (10%)
  Unknown 4 (3%)
AJCC, American Joint Committee on Cancer.
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the clinicopathological variables of patients studied. The 
patient age at the time of diagnosis ranged from 39 to 81, with 
a median of 60.9 years. The ESCC patients were classified as 
follows: AJCC stage I (n = 28), stage IIA (n = 14), stage IIB 
(n = 26), and stage III (n = 46).
Global DNA Hypomethylation of ESCC is 
Higher than Normal Esophagus Epithelium
The LINE-1 U index level of ESCC specimens, includ-
ing both primary tumors and metastatic lymph nodes (n = 140, 
mean = 0.52 ± 0.18), was significantly higher than adjacent 
normal esophageal epithelia (n = 28, mean = 0.11 ± 0.097; p 
< 0.0001). However, no difference was seen between primary 
tumors and metastatic lymph nodes (Fig. 1A and B). With 
respect to AJCC staging, LINE-1 U index level of greater 
than or equal to T2 tumors (n = 69, mean = 0.55 ± 0.18) 
was significantly higher than that of T1 tumors (n = 45, 
mean = 0.48 ± 0.15; p = 0.034; Fig. 1C). There was no 
significant association between LINE-1 U index and AJCC 
stages (data not shown). The receiver operating characteris-
tics curve for primary ESCC compared with adjacent normal 
mucosa showed an area under the curve of 0.95 (Fig. 1D).
Genome-Wide DNA Methylation 
Analysis of ESCC and Normal Esophagus 
Identified Hypermethylated TRG
To detect aberrantly methylated TRGs in ESCC, 
genome-wide DNA methylation data was analyzed for 12 
normal esophagus and 38 ESCC specimens (Supplementary 
Table 2, SDC 1, http://links.lww.com/JTO/A757). A total 
of 1631 CpG sites presented significantly (false discovery 
rate; p < 0.05) different methylation levels between normal 
and tumor tissues (Fig. 2A). Terrain maps generated with 
the methylation level of these 1631 CpG sites identified two 
independent clades containing ESCCs and normal tissues 
(Fig. 2B). Hierarchical cluster analysis using the 1631 CpG 
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FIGURE 1.  Comparison of LINE-1 U index between: A, Normal epithelium versus ESCC. B, Normal epithelium versus primary 
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sites identified two independent clusters (Fig. 2C). Among 
the most significantly hypermethylated CpG sites in ESCC, 
we identified six regions located in the promoter regions of 
RARB, RASSF1, APC, and RUNX3 genes and in two different 
regions of the gene CDKN2A, one regulating the expression 
of the p14ARF and the other regulating p16INK4a isoforms.
Specific TRGs Hypermethylated in ESCC
To validate the hypermethylation of the identified 
regions, an independent large cohort of ESCC primary tumors 
(n = 114) was analyzed by targeted MSP. Promoter hyper-
methylation of RARB, p16INK4a, RASSF1, APC, RUNX3, 
and p14ARF were observed in 55%, 24%, 20%, 19%, 14%, 
and 8% of ESCC specimens, respectively (Table 2). The pro-
moter CpG island regions of all six TRGs were unmethylated 
in adjacent normal esophageal epithelium. The frequency of 
promoter hypermethylation of APC was significantly higher in 
greater than or equal to T2 tumors (p = 0.024) and correlated 
with AJCC stage (p = 0.032), whereas the frequency of hyper-
methylation of all other TRGs was not significant.
We then stratified methylation status according to the 
distribution of hypermethylated regions of TRGs. Because 
of the low hypermethylation frequency, p14ARF gene was 
excluded from this analysis. The promoter CpG island meth-
ylation status was divided into two categories: high-frequency 
if greater than two TRGs were hypermethylated and low fre-
quency if less than or equal to two TRGs were hypermethyl-
ated. Patients with missing methylation data for any of the 
TRGs were excluded from the analysis. Consequently, 14 
patients were classified into high and 86 patients were clas-
sified into low-DNA methylation frequency (Table 3). There 
were no significant associations between the frequency of 
TRG hypermethylation and clinicopathological characteris-
tics of ESCC.
Interestingly, an inverse correlation was detected 
between the global methylation level (assessed by LINE-1 U 
index) and the methylation of RARB gene. LINE-1 U index 
was significantly higher in the RARB hypermethylated group 
(n = 52, mean = 0.59 ± 0.17) than in the RARB unmethylated 
group (n = 42, mean = 0.48 ± 0.17; p = 0.0065; Fig. 3).
To assess possible variations on TRG DNA methylation 
statuses during ESCC progression to lymph node metastasis, a 
cohort of 20 available patients having lymph node metastases 
were analyzed. Overall, a high concordance on methylation 
status of all the TRGs was observed between primary tumors 
and paired lymph node metastases (greater than 70%). Yet, 
interestingly, de novo hypermethylation of RUNX3 (15.8%), 
RARB (5.8%), and p14ARF (5%) were detected during the 
progression from primary to lymph node metastasis.
Survival Analyses of LINE-1 and TRGs 
Methylation Status in ESCC Patients
Log-rank test identified hypermethylation of RASSF1 
and APC genes to be significant predictors of OS. All patients 
with known methylation status for each marker were included 
in individual analyses. The unmethylated RASSF1 group 
FIGURE 2.  Genome-wide DNA methylation analy-
sis of ESCC and normal esophagus tissues identifies 
differential methylation of 1631 CpG sites surround-
ing 160 TRGs. A, Volcano plot depicting CpG sites 
showing significant (orange line; FDR-p = 0.05) 
hypomethylation (green dots) and hypermethylation 
(red dots) in ESCC specimens. B, The terrain map 
analysis using Euclidean metric distance revealed a 
complete separation between normal tissues and 
ESCC. C, Unsupervised hierarchical cluster analysis. 
The methylation status in ESCC (black bar) and 
normal esophagus specimens (grey bar) were identi-
fied in two independent clusters (bootstrap = 100). 
ESCC, esophageal squamous cell carcinoma; TRG, 
tumor-related gene; FDR, false discovery rate.
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(p = 0.0056, median survival = 98 months versus 23.5 months, 
n = 109) and the unmethylated APC group (p = 0.0069, median 
survival = 41.5 months versus 15 months, n = 109) had signifi-
cantly better OS than each respective methylated group (Fig. 
4A and B). Patients were then divided into two groups based 
on the number of methylated genes (greater than two versus 
less than or equal to two, range: 0–4) among RASSF1, RARB, 
p16INK4a, APC, and RUNX3 as outlined above, and survival 
association was examined. A higher number of methylated 
genes (>2 versus ≤2) was related to worse OS (p = 0.0028) 
by log-rank test (Fig. 4C), and showed 258% higher risk of 
death compared with those who had ≤ two methylated genes. 
A stepwise multivariate Cox regression analysis identified 
the number of metastatic lymph nodes, RASSF1, and APC to 
be significant predictors of OS (p < 0.0001). A proportional-
ity test conducted on the data demonstrated that the propor-
tional hazard assumption held true. As one metastatic node 
increased, the risk of death increased by 11% (HR = 1.108, 
95% CI: 1.066–1.151; p < 0.0001), methylation of RASSF1 
increases risk of death by 78% (HR = 1.779, 95% CI: 1.002–
3.159; p = 0.049), and methylation of APC increases risk of 
death by 108% (HR = 2.078, 95% CI: 1.143–3.775; p = 0.016) 
compared with the unmethylated group. LINE-1 hypomethyl-
ation level was not associated with survival outcome.
DISCUSSION
Recent studies have described epigenetic aberrations 
and their critical role in cancer progression and prognosis.12,20 
Most studies have focused on aberrant DNA methylation 
status of the promoter regions in TRGs and their silencing 
effects. Our study initially focused on significant differences 
in hypomethylation of LINE-1 between primary ESCC speci-
mens and normal esophageal epithelia not correlating with 
AJCC stage and clinical outcome. Our results suggested that 
LINE-1 hypomethylation may be an early event during ESCC 
carcinogenesis and primary tumor development. This obser-
vation was supported by our finding that LINE-1 hypometh-
ylation level was not significantly different between primary 
ESCC tumors and metastatic lymph nodes. A recent report 
also showed LINE-1 methylation levels of primary colorectal 
cancers are similar to those of matched liver and LN metas-
tases, suggesting that LINE-1 hypomethylation may occur 
in early tumorigenesis and remains relatively stable during 
progression in colorectal cancers.36 LINE-1 hypomethylation 
level of primary ESCC specimens was also significantly cor-
related with depth of tumor invasion. Although there was no 
significant correlation between LINE-1 hypomethylation and 
AJCC stage, this may be because in most ESCC cases lymph 
node metastases are frequently found, even in T1 tumors, 
when diagnosed and are classified into a worst prognosis 
group. In our series, 18 of 45 T1 tumors (40%) had lymph 
node metastases (classified into stage IIB), which is the most 
important prognostic factor in ESCC.2 Prognostic significance 
was not observed regarding LINE-1 hypomethylation level 
in our study, which is inconsistent with a recent report dem-
onstrating that LINE-1 hypomethylation of primary ESCC is 
significantly associated with disease-free survival and cancer-
specific survival.17 An explanation for this inconsistency is the TA
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clear imbalance in the stage of patients studied. Iwagami et 
al. demonstrated that LINE-1 hypomethylation is associated 
with poor prognosis in ESCC; however, there were no signifi-
cant differences when the analysis was restricted to advanced 
cases (stages II and III). Iwagami’s study included only 54% 
of advanced cases, whereas our study was mostly composed 
(75%) of patients with advanced stages.
The number of epigenetic aberrations of multiple TRGs 
assessed by MSP has been correlated with increased cellu-
lar dysplasia in ESCC tumors.37 In this regard, using TCGA 
data, we identified significant hypermethylation of six regions 
located in RARB, RASSF1, APC, RUNX3, p16INK4a, and 
p14ARF genes in ESCC. This observation was then vali-
dated in an independent large cohort of ESCCs using targeted 
MSP. We found that APC promoter hypermethylation corre-
lates with depth of tumor invasion and AJCC stage. Previous 
studies investigating ESCC primaries demonstrated that 
APC promoter hypermethylation is a prognostic biomarker. 
However, the frequency of APC promoter hypermethylation 
was shown to be greater than 40%,21,26,38 which is higher than 
the frequency detected in our study (19%). This discrepancy 
may be because of differences in the patient selection crite-
ria, because in our cohort, all the advanced T4 cases treated 
with neoadjuvant chemotherapy were excluded. Our results 
indicated that patients with APC gene hypermethylation have 
a poorer survival rate. In addition, it has been reported that 
the down-regulation of both RASSF1 transcripts and pro-
teins expression in ESCC tissues is significantly associated 
with World Health Organization grade, tumor status, and 
lymph node metastasis.39 In our study, RASSF1 gene hyper-
methylation was also associated with poorer survival rates. 
Furthermore, our analyses also revealed that the number of 
hypermethylated genes was an independent predictor of 
shorter survival.
Our analysis was also extended to evaluate variations 
of DNA methylation during the progression to lymph node 
metastasis. The methylation of the TRG panel showed a high 
concordance between primary ESCC and lymph node metas-
tases. However, two of these genes, RARB and RUNX3, pre-
sented hypermethylation status increase in lymph nodes in 
up to 29% and 26% of the cases, respectively. The observed 
enhancement on DNA methylation of this panel of TRGs may 
be a cause or a consequence of the lymph node metastasis. To 
elucidate this interesting question, a larger cohort of paired 
primary tumors and lymph node metastases will need to be 
assessed.
In addition to the clinical associations, we observed sig-
nificant relation between epigenetic events. A significant inverse 
correlation between LINE-1 hypomethylation and RARB pro-
moter hypermethylation was detected. This suggests that pro-
moter hypermethylation of specific genes may be related to 
LINE-1 hypomethylation status. Hypomethylation status of 
LINE-1 in various cancers has been suggested to be related 
to genomic instability and aberrant hypermethylation of other 
TRGs.20 However, this relation is not yet clearly understood.
Trimodality therapy or preoperative chemoradiotherapy 
followed by surgery is widely accepted as the standard of care 
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FIGURE 3.  Comparison of LINE-1 U index between RARB 
hypermethylated group versus RARB unmethylated group. 
p values were obtained by Wilcoxon test. LINE-I, long 
 interspersed nucleotide element-1.
TABLE 3.  Correlation of CpG Island methylation Status with Tumor Progression
Total Numbers of Hypermethylated Genes
0 1 2 3 4
T stage analysis
  T1 (n = 39) 15 (38%) 17 (44%) 4 (10%) 3 (8%) 0 (0%)
  ≥T2 (n = 61) 14 (23%) 25 (41%) 11 (18%) 7 (11%) 4 (7%)
  Total (n = 100) 29 (29%) 42 (42%) 15 (15%) 10 (10%) 4 (4%)
AJCC stage analysis
  Stage I (n = 23) 11 (48%) 8 (36%) 2 (8%) 2 (8%) 0 (0%)
  Stage IIA (n = 13) 2 (15%) 6 (47%) 2 (15%) 3 (23%) 0 (0%)
  Stage IIB (n = 23) 7 (30%) 11 (48%) 4 (17%) 1 (5%) 0 (0%)
  Stage III (n = 41) 9 (22%) 17 (41%) 7 (17%) 4 (10%) 4 (10%)
  Total (n = 100) 29 (29%) 42 (42%) 15 (15%) 10 (10%) 4 (4%)
AJCC, American Joint Committee on Cancer.
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for patients with locoregional esophageal squamous or ade-
nocarcinomas.40,41 Until recent years, surgical resection was 
the standard treatment for AJCC stage II/III ESCC; however, 
neoadjuvant chemotherapy with cisplatin plus 5-fluorouracil 
followed by surgery has currently emerged as a new standard 
treatment in Japan.42,43 Importantly, the cohort of patients 
enrolled in our study did not receive any neoadjuvant therapy; 
therefore, the tumor tissues are considered to contain higher 
quality DNA because of avoidance of radiation/chemother-
apy-induced DNA damage. Our findings of the significant 
association between LINE-1 and TRGs methylation status and 
ESCC may be useful for future postoperative treatment and 
management strategy decisions upon first diagnosis. For the 
future, biomarkers will be needed for prediction of preopera-
tive chemoradiotherapy because this treatment approach is a 
currently accepted practice in most Asian countries.42 Also, 
the identification of early risk factors of ESCC upon biopsy 
may be important as there is evidence of dietary prevention for 
reducing ESCC.8,9 Epigenetic events are reversible; therefore, 
development of prevention protocols in patients who have 
high-risk precancerous or early stage ESCC may be important 
especially because ESCC becomes very difficult to treat once 
it progresses. Thus, early prevention strategies to prevent or 
reverse inactivation of TRGs may be beneficial.
Currently, there are no biomarkers to identify which 
patients are likely to be at high risk for aggressive ESCC. 
Discovery of such biomarkers is important for better man-
agement of patients and stratification for treatment pur-
poses. Our results using a large number of samples implied 
that clinical tests of epigenetic aberrations of noncoding 
genomic regions LINE-1 and TRGs may serve as biomark-
ers for novel screening and clinical management of ESCC. 
Furthermore, there is potential to test these methylation bio-
markers in endoscopic surveillance biopsies or serial serum 
collection after surgery to detect early ESCC or stratify 
patients who are at higher risk for recurrence. Future studies 
will involve validation of these epigenetic biomarkers in a 
multi-institutional treatment study.
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